Physician profile
Anna Potash
NPI 1598760019
$11,270.85
in general payments reported to CMS, 2019-2025
23 companies · $2,551 in 2025
The $2,551 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,026 · 2020: $718 · 2021: $1,140 · 2022: $894 · 2023: $1,680 · 2024: $2,261 · 2025: $2,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,439 · Education: $54.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,438.52 |
| Education | $54.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $3,075.41 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,252.64 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,056.84 | 2021-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $833.36 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $772.52 | 2023-2025 | Auvelity |
| Abbvie INC. | $651.83 | 2021-2025 | |
| Lundbeck LLC | $504.16 | 2019-2024 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $359.87 | 2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $342.17 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $328.50 | 2019-2020 | |
| Almatica Pharma LLC | $296.84 | 2023-2025 | Loreev Xr, Gralise |
| Takeda Pharmaceuticals U.S.A., INC. | $272.67 | 2019-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $253.57 | 2019-2025 | Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $251.55 | 2019-2020 | |
| Bausch Health US, LLC | $219.90 | 2019-2025 | Aplenzin |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $201.48 | 2020-2022 | |
| Allergan, INC. | $199.23 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $90.33 | 2020-2023 | |
| Shire North American Group INC | $74.78 | 2019 | |
| Neos Therapeutics, Lp | $69.64 | 2019-2025 | Exxua |
| Eisai INC. | $67.52 | 2020 | |
| Vanda Pharmaceuticals INC. | $54.03 | 2024 | Fanapt |
| Idorsia Pharmaceuticals US INC | $42.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Potash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.